Researcher
Dirk Hose
- Keywords:Medicine
Affiliations
- Hematology (Research group)
Member
From22 Mar 2021 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Mar 2020 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Mar 2020 → 20 Oct 2022
Publications
11 - 20 of 109
- JunB is a key regulator of multiple myeloma bone marrow angiogenesis(2021)
Authors: Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Eugenio Morelli, Qinyue Jiang, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, et al.
Pages: 3509-3525 - Publisher Correction(2021)
Authors: Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, Jose Manuel Garcia-Manteiga, Eugenio Morelli, Qinyue Jiang, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt, et al.
- Publisher Correction(2021)
Authors: Elias K Mai, Kaya Miah, Uta Bertsch, Jan Dürig, Christof Scheid, Katja C Weisel, Christina Kunz, Markus Munder, Hans-Walter Lindemann, Maximilian Merz, et al.
Pages: 3636-3636 - Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics(2021)
Authors: Stephan M Tirier, Jan-Philipp Mallm, Simon Steiger, Alexandra M Poos, Mohamed H S Awwad, Nicola Giesen, Nicola Casiraghi, Hana Susak, Katharina Bauer, Anja Baumann, et al.
- Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis(2021)
Authors: Cyrus Khandanpour, Christine Eisfeld, Subbaiah Chary Nimmagadda, Marc S Raab, Niels Weinhold, Anja Seckinger, Dirk Hose, Anna Jauch, Asta Försti, Kari Hemminki, et al.
- Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial(2021)
Authors: Eva-Maria Klein, Diana Tichy, Hans J Salwender, Elias K Mai, Jan Duerig, Katja C Weisel, Axel Benner, Uta Bertsch, Mabast Akhavanpoor, Britta Besemer, et al.
- Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis(2021)
Authors: Marco Basset, Christoph R Kimmich, Nicholas Schreck, Julia Krzykalla, Tobias Dittrich, Kaya Veelken, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, et al.
Pages: 230-243 - Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial(2021)
Authors: Hans J Salwender, Ahmet Elmaagacli, Maximilian Merz, Kaya Miah, Axel Benner, Mathias Haenel, Christian Jehn, Elias K Mai, Uta Bertsch, Igor W Blau, et al.
Pages: 3007-3011 - CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma(2021)
Authors: Chunyan Gu, Wang Wang, Xiaozhu Tang, Tingting Xu, Yanxin Zhang, Mengjie Guo, Rongfang Wei, Yajun Wang, Artur Jurczyszyn, Siegfried Janz, et al.
- RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma(2021)
Authors: Chunyan Gu, Ting Lu, Wang Wang, Miaomiao Shao, Rongfang Wei, Mengjie Guo, Rui Li, Li Qiao, Ye Hu, Fenghuang Zhan, et al.
Pages: 1803-1807